Clinical Trial: A Phase I Study of Liposomal Irinotecan (Nal-IRI, ONIVYDE(R)) Plus Cisplatin in Patients With Advanced or Metastatic Solid Malignancies.

U.S., Aug. 25 -- ClinicalTrials.gov registry received information related to the study (NCT07782346) titled 'A Phase I Study of Liposomal Irinotecan (Nal-IRI, ONIVYDE(R)) Plus Cisplatin in Patients With Advanced or Metastatic Solid Malignancies.' on Aug. 19.

Brief Summary: Phase I trial, Multiple centers, open-label, non-randomized single-arm study

Study Start Date: Oct. 01

Study Type: INTERVENTIONAL

Condition: Advanced Solid Malignancies

Intervention: DRUG: Liposomal Irinotecan Plus Cisplatin

Liposomal irinotecan and cisplatin are administered intravenously on Days 1 and 15 of each 28-day cycle.

Recruitment Status: NOT_YET_RECRUITING

Sponsor: National Health Research Institutes, Taiwan

Disclaimer: Curated by HT Syndication....